What clinical trials are available for metastatic Thyroid Cancer

Clinical Trials for Metastatic Thyroid Cancer

I appreciate your question about clinical trial options. While I can provide educational information about how thyroid cancer clinical trials are typically structured and what types of research are available, I don't have access to a real-time database of currently enrolling trials. Let me explain what you should know and how to find the right trials for your situation.

Types of Clinical Trials for Metastatic Thyroid Cancer

According to the NCCN Guidelines for Thyroid Carcinoma, clinical trials play an important role in treatment planning. The guidelines specifically state: "Enrollment in neoadjuvant clinical trials should be encouraged" for patients with metastatic disease.

Common Research Areas in Thyroid Cancer Trials:

1. Targeted Therapy Trials

• Kinase inhibitors (drugs that block specific cancer growth pathways) are a major focus
• These include agents like lenvatinib, sorafenib, cabozantinib, and sunitinib
• Trials test effectiveness, optimal dosing, and side effect management

2. Mutation-Specific Trials According to NCCN Guidelines, trials may focus on patients with specific genetic mutations:

• BRAF mutations → tested with BRAF inhibitors (like dabrafenib/trametinib)
• RET mutations → tested with RET inhibitors (selpercatinib, pralsetinib)
• NTRK fusions → tested with TRK inhibitors (larotrectinib, entrectinib)
• ALK fusions → tested with ALK inhibitors

3. Immunotherapy Trials

• Anti-PD-1 antibodies like pembrolizumab are being studied
• These work by helping your immune system recognize cancer cells

4. Combination Therapy Trials

• Testing kinase inhibitors combined with other drugs
• Testing radiation therapy combined with systemic therapy

How to Find Clinical Trials

Primary Resource: ClinicalTrials.gov

• Visit www.ClinicalTrials.gov
• Search terms to use:
  • "Thyroid cancer" + "metastatic"
  • Specific drug names (lenvatinib, cabozantinib, etc.)
  • Your specific mutation if known (BRAF, RET, NTRK, ALK)

Other Resources:

• National Cancer Institute (NCI): cancer.gov/about-cancer/treatment/clinical-trials
• American Cancer Society: cancer.org/treatment/find-clinical-trials
• Your oncology team can identify trials matching your specific disease characteristics

Questions to Ask Your Oncology Team

Since clinical trial eligibility depends on YOUR specific situation, ask your doctor:

1. "Are there any clinical trials that match my specific thyroid cancer type and stage?"

   • Different trials accept different histologies (papillary, follicular, medullary, anaplastic)

2. "Has my tumor been tested for mutations (BRAF, RET, NTRK, ALK)? Are there mutation-specific trials available?"

   • This testing can open doors to targeted therapy trials

3. "What is my current disease status—is my cancer radioactive iodine-refractory?"

   • This determines which trials I'm eligible for

4. "What are the inclusion and exclusion criteria for trials you're recommending?"

   • Understanding why you qualify (or don't) helps with decision-making

5. "How will trial participation affect my current treatment plan?"

   • Some trials replace standard treatment; others are additions

6. "What are the potential benefits and risks specific to the trials you're recommending?"

   • Each trial has different side effect profiles

Important Context from NCCN Guidelines

The NCCN Guidelines note that kinase inhibitors used in clinical trials typically show:

• Response rates of 50-60% of patients experiencing benefit (partial response or stable disease)
• Duration of benefit: usually 12-24 months
• Lenvatinib specifically showed a progression-free survival of 18.3 months compared to 3.6 months with placebo in the SELECT trial

However, these are general statistics—your individual response depends on many factors your oncologist will discuss.

Next Steps

1. Request genetic testing if not already done (BRAF, RET, NTRK, ALK mutations)
2. Ask your oncology team to review ClinicalTrials.gov with you
3. Consider a second opinion from a thyroid cancer specialist if you want additional trial options
4. Document your disease characteristics (histology, stage, prior treatments, mutation status) to share with trial coordinators

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.